Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Response of Recent Human Immunodeficiency Virus Seroconverters to the Pneumococcal Polysaccharide Vaccine and Haemophilus influenzae Type b Conjugate Vaccine

Peter J. Weiss, Mark R. Wallace, Edward C. Oldfield III, James O'Brien and Edward N. Janoff
The Journal of Infectious Diseases
Vol. 171, No. 5 (May, 1995), pp. 1217-1222
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30134550
Page Count: 6
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Response of Recent Human Immunodeficiency Virus Seroconverters to the Pneumococcal Polysaccharide Vaccine and Haemophilus influenzae Type b Conjugate Vaccine
Preview not available

Abstract

Antibody responses in recent human immunodeficiency virus (HIV) seroconverters to 2 vaccines were studied. Twenty patients infected with HIV for <18 months and 15 HIV-seronegative controls were vaccinated with the 23-valent pure polysaccharide pneumococcal vaccine and the Haemophilus influenzae type b (Hib) capsular polysaccharide diphtheria $CRM_{197}$ protein toxoid conjugate vaccine in separate arms. Despite increased levels of total serum IgG, recent seroconverters and controls showed similar specific IgG responses for 6 of 7 antigens. Baseline levels were equivalent in both groups, as were peak levels of IgG at 1 month to conjugated polysaccharide (Hib), delayed-type hypersensitivity, and pneumococcal capsular serotypes 4, 6B, 12F, and 14. At 6 months, IgG levels were similar for 4 of 7 antigens. Antibody responses to pure pneumococcal capsular polysaccharides and to a protein recall antigen were most often similar among recent seroconverters and seronegative controls. Both total levels and fold-rises of IgG to the Hib conjugate were similar in the 2 groups. Immunization of HIV-infected patients soon after seroconversion rather than later appears to improve antibody responses.

Page Thumbnails

  • Thumbnail: Page 
1217
    1217
  • Thumbnail: Page 
1218
    1218
  • Thumbnail: Page 
1219
    1219
  • Thumbnail: Page 
1220
    1220
  • Thumbnail: Page 
1221
    1221
  • Thumbnail: Page 
1222
    1222